non-immunosuppressive cyclophilin inhibitor
oral activity in humanized HCV model
from semisynthetic deriv. of FR901459
Bioorg. Med. Chem. Lett., Jun. 2, 2020
Astellas Pharma, Ibaraki, JP
ASP5286 is an analog of the natural product cyclosporin A that maintains the anti-HCV activity of cyclosporin A by binding to cyclophilin, but was optimized to be less immunosuppresive than cyclosporin A. The macrocycle was identified through semisynthetic derivitization of a related natural product, FR901459. The Astellas team was able to optimize compounds from immunosuppresive compounds with poor oral exposure to the non-immunosuppressive clinical candidate 5286 with oral activity in a mouse humanized liver HCV model.